Study of IMC-11F8 in Patients With Tumors Who Have Not Responded to Standard Therapy

Phase 1

Completed

• Conditions: Solid Tumors
• Interventions: Biological: IMC-11F8; Biological: IMC-11F8 I.V.

• Registration Number: NCT00801177
• Lead Sponsor: Eli Lilly and Company

Brief Summary

The purpose of this study is to determine if IMC-11F8 is safe for patients, and also to determine the best dose of IMC-11F8 to give to patients.

Detailed Description

The purpose of this study is to establish the safety profile and the maximum tolerated dose (MTD) of the fully human anti-EGFR monoclonal antibody IMC-11F8 in patients with solid tumors who have filed standard therapy or for whom no standard therapy is available.

Study Timeline

• Study Start: 2004-11
• Primary Completion: 2007-02
• Study Completion: 2007-02
• Study First Submitted: 2008-12-02
• Study First Submitted QC: 2008-12-02
• Study First Posted: 2008-12-03
• Status Verified: 2010-10
• Last Update Submitted: 2010-10-11
• Last Update Posted: 2010-10-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• Histologically-confirmed, EGFR-detectable or EGFR-undetectable, unidimensionally-measurable and/or evaluable solid tumors who failed standard therapy or for whom no standard therapy is available. Patients who do not have tissue available for EGFR testing will undergo a biopsy of an accessible tumor.

• ECOG performance status score of ≤ 2 at study entry.

• Able to provide written informed consent.

• White blood cell (WBC) count ≥ 3 x 109/L; an absolute neutrophil count ≥ 1.5 x 109/L; a hemoglobin level > 90 g/L; and a platelet count ≥ 100 x 109/L.

• Adequate hepatic function as defined by:

  • an alkaline phosphatase level ≤ 5.0 x the ULN
  • a bilirubin level ≤ 1.5 x the ULN
  • aspartate transaminase (AST) and alanine transaminase (ALT) levels ≤ 2.5 x the ULN or ≤ 5 x the ULN for patients with liver metastases

• Adequate renal function as defined by a serum creatinine level within normal limits.

• Use of effective contraception if procreative potential exists.

• Life expectancy of approximately 3 months in the opinion the opinion of the investigator.

Read More

Exclusion Criteria

• Chemotherapy, radiation, and/or hormonal therapy (except palliative radiation therapy for disease-related pain and chronic hormonal therapy for prostate carcinoma) within 4 weeks of study entry.
• Concurrent unstable or uncontrolled medical disease (e.g., active uncontrolled systemic infection, poorly controlled hypertension or history of poor compliance with an anti-hypertensive regimen, unstable angina, congestive heart failure, uncontrolled diabetes) or other chronic disease, which, in the opinion of the investigator, could compromise the patient or the study.
• Newly-diagnosed or symptomatic brain metastases (patients with a history of brain metastases must have received definitive surgery or radiotherapy, be clinically stable, and not taking steroids; anticonvulsants are allowed).
• Any concurrent malignancy other than basal cell carcinoma or carcinoma in situ of the cervix. Patients with a previous malignancy but without evidence of disease for ≥ 3 years will be allowed to enter the trial.
• Any condition that prevents the patient from providing informed consent.
• Pregnancy (confirmed by serum beta human chorionic gonadotropin [ßHCG]) or breast-feeding.
• Any investigational agent(s) or device(s) within 4 weeks of study entry.
• Prior treatment with cetuximab, or any other epidermal growth factor receptor inhibitors, including tyrosine kinase inhibitors, such as gefitinib or erlotinib. Prior treatment with other monoclonal antibodies targeting receptors other than the EGFR is permitted ≥ 4 weeks prior to study entry.
• Any prior therapy that targeted the EGFR or EGFR pathway.
• Known history of human immunodeficiency virus.
• Employees of the investigator or study center with direct involvement in this study or other studies under the direction of the investigator or study center, as well as family members of the employees.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
IMC-11F8 (Every week)	IMC-11F8	Cycle of therapy administered intravenously, once a week for 6 weeks, for a total of six doses per cycle.
IMC-11F8 (Every week)	IMC-11F8 I.V.	Cycle of therapy administered intravenously, once a week for 6 weeks, for a total of six doses per cycle.
IMC-11F8 (Every other week)	IMC-11F8	Cycle of therapy administered intravenously, every other week for 6 weeks, for a total of three doses per cycle.

Primary Outcome Measures

Name	Time	Method
Number of Participants with Adverse Events	Approximately 24 Months
Maximum Tolerated Dose of IMC-11F8	Approximately 24 Months

Secondary Outcome Measures

Name	Time	Method
Area under the Time Concentration Curve (AUC)	Approximately 24 Months
Maximum concentration (Cmax)	Approximately 24 Months
Half-life (t 1/2)	Approximately 24 Months
Serum Anti-IMC-11F8 Antibody Assessment	Approximately 24 Months
Change from baseline in Antitumor Activity	Approximately 24 Months

Trial Locations

Locations (1)

ImClone Investigational Site; 🇳🇱 Utrecht, Netherlands